Ponesimod PONVORY: Novel Oral Treatment Option for Multiple Sclerosis

　　1.Mechanism of Action

　　Ponesimod is a highly selective S1P1 receptor modulator.By specifically binding to S1P1 receptors,ponesimod induces lymphocyte migration from peripheral blood to lymph nodes,reducing autoreactive lymphocytes entering the central nervous system,thereby alleviating neuroinflammation.This mechanism is similar to fingolimod and siponimod,but ponesimod demonstrates higher selectivity for S1P1 receptors,theoretically reducing cardiovascular and other adverse effects.

　　2.Comparison with Traditional Oral Medications

　　Compared to traditional oral MS medications such as teriflunomide and fingolimod,ponesimod offers the following advantages:relatively faster onset of action;shorter lymphocyte recovery time after discontinuation;higher selectivity for S1P receptor subtypes.Clinical studies show ponesimod demonstrates positive effects in reducing annual relapse rates and delaying disability progression.Specific medication selection requires comprehensive evaluation based on individual patient circumstances.

　　3.Comparison with Traditional Injectable Medications

　　Compared to injectable medications such as interferon beta and glatiramer acetate,ponesimod as an oral formulation offers greater convenience without frequent injections,potentially improving patient adherence.However,injectable medications have accumulated extensive safety data through long-term use,and some patients may be more suitable for injectable treatment.Both options have advantages,and selection should comprehensively consider efficacy,safety,and administration convenience.

　　4.Safety and Adverse Reactions

　　Common adverse reactions of ponesimod include headache,liver function abnormalities,hypertension,and decreased heart rate.Due to its S1P modulating effects,a dose titration regimen is required during initial use to reduce cardiac-related adverse reactions.Serious adverse reactions may include increased infection risk and skin cancer risk.ECG examination and liver function assessment are recommended before initiating treatment.

　　5.Treatment Selection Recommendations

　　There is no absolutely"superior"treatment option;selection should be based on individual patient circumstances.For patients preferring oral medication and willing to accept regular monitoring,ponesimod is a suitable choice;for patients with inadequate response or intolerance to other disease-modifying therapies,ponesimod can serve as an alternative;patients with underlying cardiovascular conditions require more careful evaluation.Physicians will develop individualized treatment plans based on disease activity,comorbidities,and previous treatment history.